PRXL2C: A Drug Target / Disease Biomarker (G195827)

Target Name: PRXL2C

NCBI ID: G195827

PRXL2C

PRXL2C: A Drug Target / Disease Biomarker

PRXL2C, also known as ALX148, is a drug target and a potential biomarker for the treatment of various diseases, including cancer. PRXL2C is a transmembrane protein that is expressed in various tissues and cells in the body. Its function is not yet fully understood, but research has shown that it plays a role in the regulation of cellular processes, including cell adhesion, migration, and angiogenesis.

One of the main research focuses on PRXL2C is its potential as a drug target. PRXL2C has been shown to be involved in several signaling pathways, including the TGF-β pathway. This pathway is known to play a role in the development and progression of many diseases, including cancer. By targeting the PRXL2C protein, researchers are targeting a potential drug that can inhibit the activity of PRXL2C and lead to the inhibition of these signaling pathways.

Another research focus on PRXL2C is its potential as a biomarker. PRXL2C has been shown to be expressed in various tissues and cells, including cancer cells, and it has been used as a biomarker for cancer diagnosis and monitoring. By measuring the level of PRXL2C in cancer cells, researchers can monitor the effectiveness of different treatments and track the disease progression.

In addition to its potential as a drug target and biomarker, PRXL2C has also been shown to have several potential therapeutic applications. For example, PRXL2C has been shown to be involved in the regulation of cell adhesion, which is important for the development of cancer. By inhibiting the activity of PRXL2C, researchers may be able to promote cell migration and invasion, which could be a potential therapeutic approach for cancer treatment.

Another potential application of PRXL2C is its role in the regulation of angiogenesis. Angiogenesis is the process by which new blood vessels are formed in the body, and it is involved in the development of many diseases, including cancer. By targeting the PRXL2C protein, researchers may be able to inhibit the activity of PRXL2C and reduce the formation of new blood vessels, which could be a potential therapeutic approach for cancer treatment.

In conclusion, PRXL2C is a protein that has been shown to play a role in several cellular processes, including cell adhesion, migration, and angiogenesis. As a potential drug target and biomarker, PRXL2C has the potential to lead to new therapeutic approaches for the treatment of various diseases, including cancer. Further research is needed to fully understand the function of PRXL2C and its potential therapeutic applications.

Protein Name: Peroxiredoxin Like 2C

Functions: May regulate positively ERK1/2 signaling and AKT1 activation leading to HIF1A up-regulation with an increased expression of glycolysis genes and enhanced glycolysis

The "PRXL2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRXL2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets